2Cosmi B ,Filippini M,Campana F,et al. Risk factors for recurrent events in subjects with superficial vein thrombo- sis in the randomized clinical trial steflux (superficial thromboembolism fluxum) [J]. Thrombosis Research,2014, 133(2):196-202.
3Puymirat E,Aissaoui N,Collet JP,et al. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients [J]. Inter J Cardio, 2013,166( 1 ) : 106-110.
4Whiteley WN,Adams HP, Bath PMW,et al. Targeted use of heparin,heparinoids,or low -molecular -weight heparin to improve outcome after acute ischaemic stroke:an individual patient data meta-analysis of ran- domised controlled trials [J]. Neurology,2013,12 (6): 539-545.
5Avidan MS,Smith JR, Skrupky LP,et al. The occurrence of antibodies to heparin-platelet factor 4 in cardiac and thoracic surgical patients receiving desirudin or heparin for postoperative venous thrombosis prophylaxis [J]. Thrombosis Research, 2011,128 (6) : 524-529.
6Goldenberg NA,Branchford B,Wang M,et al. Percuta- neous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects :findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism [J]. Journal of Vascular and Interven- tional Radiology ,2011,22(2) : 121-132.
7Argenta C,Ferreira MAP,Sander GB,et al. Short-term therapy with enoxaparin or unfractionated heparin for ve- nous thromboembolism in hospitalized patients:utiliza- tion study and cost-minimization analysis [J]. Value in Health, 2011,14(5) : 89-92.
